

Mytide Therapeutics, Agilent collaborate on automation solutions for Mytide's BioFab2 platform

18 August 2022 | News

Agilent will supply analytical and preparative chromatography equipment for Mytide's discovery and personalised therapeutics technology platform



Mytide Therapeutics, a company transforming peptide manufacturing with predictive analytics and machine learning, has partnered with Agilent, a global leader in life science, diagnostic and applied chemical markets. The two companies will collaborate on robust, scalable and reliable automation solutions for Mytide's BioFab2 platform, a technology suite that combines chemistry, robotics and machine learning to advance and accelerate peptide and peptide conjugate manufacturing.

Under the terms of the agreement, Agilent will supply analytical and preparative chromatography equipment for Mytide's BioFab2 fleet. The ultimate aim of the partnership is to drive clinical impact by accelerating the development of life-saving therapeutics.

Together, Mytide and Agilent will leverage their combined technologies and analytical processes to help address known bottlenecks in peptide development and manufacturing by improving process performance and reliability. Mytide's BioFab2 platform leverages advances in chemistry, robotics and AI to access natural and non-natural peptides faster than typical processes. Leveraging this suite of capabilities, Mytide is continuing to build datasets and technologies to drive access beyond easily accessible biopolymer which includes peptide-drug conjugates, constrained peptides, and short proteins.